Generic Name and Formulations:
Interferon beta-1a 30mcg per prefilled syringe (albumin-free liq) or per vial [pwd for reconstitution (preservative-free, contains albumin)]; or per prefilled autoinjector (albumin-free liq); for IM inj.
Indications for AVONEX:
Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations in patients with first clinical episode and MRI consistent with MS.
Pre-medicate with analgesics and/or antipyretics on treatment days to ameliorate flu-like symptoms. Rotate inj sites. ≥18yrs: 30mcg IM once weekly. May titrate dose to reduce severity of flu-like symptoms; dosed once weekly, IM: Week 1: 7.5mcg. Week 2: 15mcg. Week 3: 22.5mcg. Week 4: 30mcg.
<18yrs: not established.
Monitor for signs/symptoms of hepatic injury. Depression. Suicidal ideation. Seizure disorders. Pre-existing CHF: monitor for worsening cardiac function at initiation and during treatment. Risk of thrombotic microangiopathy; discontinue if occurs. Myelosuppression. Monitor CBCs, differential, platelets, blood chemistries, liver and thyroid function. Consider discontinuing if new autoimmune disorder develops. Pregnancy (Cat.C; may be abortifacient). Nursing mothers.
Risk of hepatic injury with concomitant hepatotoxic drugs or alcohol.
Flu-like symptoms, asthenia, headache, myalgia, fever, chills, GI upset, depression, blood dyscrasias, seizures; rare: hepatic injury, anaphylaxis (discontinue if occurs).
Register pregnant patients exposed to Avonex by calling (800) 456-2255.
Single-use prefilled syringes (0.5mL) dose pack—1 (4 syringes, supplies); Single-use vial dose pack—1 (4 vials, diluent, supplies); Single-use prefilled autoinjector (0.5mL) dose pack—1 (4 autoinjectors, supplies)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|